Johnson & Johnson will spin off its $9.2B orthopedics business into a new company, DePuy Synthes, to focus on faster-growing ...

The planned separation is the latest move by J&J to slim down in recent years and focus on faster-growing businesses.

Johnson & Johnson (NYSE: JNJ) announced today that it intends to separate its DePuy Synthes Orthopaedics business.

Johnson & Johnson reported third-quarter sales of $24 billion, beating the FactSet consensus estimate of $23.8 billion.

Beyond the banks, we hear from Johnson & Johnson, which should have the strongest numbers of any pharmaceutical company.

Johnson & Johnson said on Tuesday it plans to separate its orthopedics business into a standalone company within the next 18 ...

Johnson & Johnson raises 2025 sales forecast and beats quarterly estimates, while announcing plans to spin off its $9.2 ...

Johnson & Johnson’s stock rose toward a record after a beat-and-raise earnings report and announcement of plans to separate ...

(To receive weekly emails of conversations with the world’s top CEOs and decisionmakers, click here.) It’s nearly a year and a half since Johnson & Johnson split off its consumer-health arm to focus ...

It looks like Johnson & Johnson will have to part with nearly a billion dollars. A Los Angeles jury ordered Johnson & Johnson ...

Johnson & Johnson has a strong business, several growth opportunities, and a safe dividend. The company does face headwinds, but it should be able to overcome them. Some might describe Johnson & ...